Aristides Capital’s TherapeuticsMD TXMD Stock Holding History

Aristides Capital’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3,135	Closed	-$190K	–	177
2020 Q4	$190K	Buy	+3,135	New	+$214K	0.07%	126

Other funds holding TXMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aristides Capital's TXMD Position: Q1 2021 in Review

Aristides Capital sold out of TherapeuticsMD (TXMD) in Q1 2021, closing a stake of 3,135 shares — an estimated $190K sold.

Aristides Capital first reported a position in TXMD in Q4 2020 and held it in 1 quarter. The position peaked at $190K in Q4 2020. 160 funds tracked by Wall St. Rank hold TXMD as of Q1 2021.

Aristides Capital reported no remaining TherapeuticsMD position as of Q1 2021 after selling out during the quarter.
Aristides Capital sold 3,135 TherapeuticsMD shares in Q1 2021, an estimated $190K.
Aristides Capital first reported a position in TherapeuticsMD in Q4 2020 and held it in 1 quarter.
Aristides Capital's TherapeuticsMD position peaked at $190K in Q4 2020.
160 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2021.

Based on Aristides Capital's 13F filing for Q1 2021, filed 17 May 2021.